Fannie Mae-No Politics (FNMA): they are lining it up. keep educating th...

they are lining it up. keep educating them

stockanalyze · 2025-03-28T17:07:00.3570000Z

they are lining it up. keep educating them , everyone do it, don't stop. information is power. truth must prevail.

Play Episode

3min

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Proactive - Interviews for investors

St George Mining unveils major JORC resource

St George Mining Ltd executive chairman John Prineas talked with Proactive about the company's newly announced maiden JORC resource, which he says could be among the world’s most significant niobium and rare earth deposits. Prineas said the deposit features over 500 intercepts of high-grade mineralisation and boasts a rare combination of high grades and shallow mineralisation starting at surface, supporting an open pit development. “We think, possibly the second highest niobium deposit in terms of grade and, probably one of the highest rare earth deposits,” he told Proactive. He confirmed the company has already seen interest from industry players, with some expressing interest in potential partnerships and even mergers. The resource was released following St George’s acquisition of the project in late February, and the company has committed to a drill program starting in the coming weeks. According to Prineas, this program could potentially double the existing resource. In Brazil, St George has assembled an experienced in-country team and engaged a global EPC contractor to progress mine development. The company has also begun metallurgical and downstream processing studies and believes the project will deliver a commercial-grade product, supported by decades of similar production by neighbours CBMM. 👉 For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. #StGeorgeMining #Niobium #RareEarths #JORCResource #MiningExploration #ASX #CriticalMinerals #BrazilMining #ResourceUpdate #MineralDiscovery #JohnPrineas #ProactiveInvestors

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Followers	59
Posts	5507
Boards Moderated	0
Alias Born	09/08/2012

Volume:	16,044,402
Day Range:	5.17 - 5.80
Bid:	5.50
Ask:	5.74
Last Trade Time:	4:49:25 PM EDT
Total Trades:	16,504

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

FNMA Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free